HPLC + MS
Independently tested for identity and purity
NP-CJC-001
Apr 16, 2026
99.41%
View Certificate of Analysis
Also Known As CJC-1295 DAC
Target GHRHR
Class Long-Acting Synthetic GHRH Analogue
Form Lyophilized Powder
Receptor Target
Peptide Length
Long-Acting
CJC-1295 with DAC is a synthetic 29-amino-acid growth hormone releasing hormone (GHRH) analogue incorporating a Drug Affinity Complex (DAC) — a maleimido-propionyl (MPA) bioconjugate group that enables the peptide to covalently bind serum albumin at Cys-34 upon introduction into a biological system. This albumin-binding property substantially extends the compound’s signalling duration compared with CJC-1295 without DAC (Mod GRF 1-29), making it a distinct pharmacological tool for prolonged GHRHR pathway research in preclinical models. Supplied by NexPept as a lyophilized powder for in vitro laboratory research use. This compound has not been authorized by Health Canada for any therapeutic, clinical, or human use.
Molecular Profile
Sequence, modification, molecular weight, analytical data
Sequence, modification, molecular weight, analytical data
| Property | Value |
|---|---|
| Research Designation | CJC-1295 DAC; CJC-1295 with Drug Affinity Complex |
| Compound Class | Synthetic 29-AA GHRH analogue — DAC-modified, long-acting GHRHR agonist |
| Sequence Length | 29 amino acids (same backbone as Mod GRF 1-29) |
| DAC Modification | Maleimido-propionyl (MPA) group — enables covalent binding to serum albumin Cys-34 |
| Approximate MW | ~3,647 Da (peptide + DAC moiety). Albumin-bound complex ~67 kDa. |
| MW vs No DAC | CJC-1295 No DAC (Mod GRF 1-29) is ~3,368 Da. The ~279 Da difference is the DAC moiety and is the clearest way to tell the two apart on a CoA. |
| Receptor Target | GHRHR (Growth Hormone Releasing Hormone Receptor) |
| Key Distinction vs No DAC | Extended signalling duration via albumin conjugation — contrasts with the shorter, pulsatile GHRHR signalling model of CJC-1295 No DAC |
| Physical Form | Lyophilized powder |
| Analytical Method | High-Performance Liquid Chromatography (HPLC) + Mass Spectrometry (MS) |
| Appearance | White to off-white lyophilized solid |
A note on CAS numbers: CAS registry entries for CJC-1295 are inconsistent across sources, with the same number often applied to both the DAC and non-DAC forms. Molecular weight is the reliable identifier: confirm ~3,647 Da on the Certificate of Analysis for the DAC form.
In Vitro Research Context
Receptor pharmacology & DAC mechanism — laboratory use only
Receptor pharmacology & DAC mechanism — laboratory use only
A G protein-coupled receptor (GPCR) that mediates the downstream effects of endogenous GHRH, including cAMP/PKA signalling cascades. CJC-1295 with DAC is studied as a long-acting GHRHR agonist in preclinical pharmacology research, enabling investigation of sustained GHRHR pathway activation across extended in vitro and ex vivo study windows — a distinct research model from the shorter-duration signalling profile of CJC-1295 No DAC (Mod GRF 1-29).
The DAC in CJC-1295 consists of a maleimido-propionyl (MPA) bioconjugate group attached to the peptide backbone. In the presence of serum albumin, the maleimide group forms a stable thioether bond with the free cysteine residue (Cys-34) of albumin. The resulting albumin–peptide conjugate exploits albumin’s long circulatory half-life, substantially extending the duration over which the GHRHR-binding peptide remains available in biological systems. This mechanism is studied in the context of albumin-conjugate pharmacokinetics, prolonged receptor engagement models, and GHRH analogue half-life research. The two forms are compared directly in the CJC-1295 DAC vs No DAC guide.
CJC-1295 with DAC is studied in preclinical in vitro settings as a long-acting pharmacological tool for GHRHR pathway research. Comparative studies using both CJC-1295 with DAC and CJC-1295 No DAC allow researchers to examine the impact of signalling duration on downstream pathway outcomes at the same GHRHR target — the DAC version modelling sustained receptor engagement while the No DAC version models shorter pulsatile activation windows.
Research context: CJC-1295 with DAC is an investigational synthetic GHRH analogue studied in scientific research involving GHRHR signalling, albumin conjugation pharmacokinetics, and prolonged somatotropic axis pathway models. It has not been authorized by Health Canada for human or veterinary use.
Available Formats
5mg — lyophilized powder
5mg — lyophilized powder
| Format | Net Quantity | Physical Form |
|---|---|---|
| CJC-1295 With DAC 5mg | 5 mg / vial | Lyophilized powder |
Sourced from a verified batch. Quantity for use should be determined based on your specific in vitro research protocol by qualified research personnel.
Laboratory Storage
Controlled storage conditions for lyophilized material
Controlled storage conditions for lyophilized material
Store sealed lyophilized material under controlled laboratory conditions in accordance with validated institutional SOPs and applicable technical documentation. Protect from light and moisture. The maleimide group within the DAC moiety may be susceptible to hydrolysis under prolonged exposure to aqueous conditions — sealed lyophilized storage is recommended until point of use in the laboratory. This is a handling consideration specific to the DAC form and does not apply to CJC-1295 No DAC. Handling conditions should be established by qualified research personnel in accordance with the specific experimental protocol.
Note: No preparation, reconstitution, or administration instructions are provided. This compound is supplied for in vitro laboratory research use only. All handling must be conducted by qualified personnel following institutional safety protocols.
Research Literature
Scientific references & related resources
Scientific references & related resources
CJC-1295 DAC vs No DAC: What’s the Difference? — direct comparison of the two forms: structure, signalling duration, handling and research use
CJC-1295 With DAC Research Peptide Overview — NexPept compound overview and in vitro research context
PubMed — CJC-1295 DAC / GHRH albumin conjugate — peer-reviewed literature on long-acting GHRH analogues and DAC pharmacokinetics
This product is supplied exclusively for in vitro laboratory and non-clinical research use by qualified research personnel. It is not authorized by Health Canada for human or veterinary use. No therapeutic, clinical, or health claims are made.
This material must not be administered to humans or animals. No dosage, preparation, reconstitution, or administration instructions are provided or implied. All handling and use must be conducted by qualified personnel in accordance with applicable institutional policies and legal requirements.
Be the first to review “CJC-1295 With DAC 5mg”
Related products
Peptides
Reviews
There are no reviews yet.